DOCSLIB.ORG

WT1 Proteins : Functions in Growth and Differentiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WT1 Proteins : Functions in Growth and Differentiation WT1 proteins : functions in growth and differentiation Citation for published version (APA): Scharnhorst, V., Eb, van der, A. J., & Jochemsen, A. G. (2001). WT1 proteins : functions in growth and differentiation. Gene, 273(2), 141-161. https://doi.org/10.1016/S0378-1119(01)00593-5 DOI: 10.1016/S0378-1119(01)00593-5 Document status and date: Published: 01/01/2001 Document Version: Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers) Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.tue.nl/taverne Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim. Download date: 29. Sep. 2021 Gene 273 ,2001) 141±161 www.elsevier.com/locate/gene Review WT1 proteins: functions in growth and differentiation Volkher Scharnhorst, Alex J. van der Eb, Aart G. Jochemsen* Department of Molecular and Cellular Biology and Center for Biomedical Genetics, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands Received 23 March 2001; received in revised form 11 June 2001; accepted 2 July 2001 Received by A.J. van Wijnen Abstract The Wilms' tumor 1 gene ,WT1) has been identi®ed as a tumor suppressor gene involved in the etiology of Wilms' tumor. Approximately 10% of all Wilms' tumors carry mutations in the WT1 gene. Alterations in the WT1 gene have also been observed in other tumor types, such as leukemia, mesothelioma and desmoplastic small round cell tumor. Dependent on the tumor type, WT1 proteins might either function as tumor suppressor proteins or as survival factors. Mutations in the WT1 gene can also result in congenital abnormalities as observed in Denys± Drash and Frasier syndrome patients. Mouse models have proven the critical importance of WT1 expression for the development of several organs, including the kidneys, the gonads and the spleen. The WT1 proteins seem to perform two main functions. They regulate the transcription of a variety of target genes and may be involved in post-transcriptional processing of RNA. The WT1 gene encodes at least 24 protein forms. These isoforms have partially distinct biological functions and effects, which in many cases are also speci®c for the model system in which WT1 is studied. This review discusses the molecular mechanisms by which the various WT1 isoforms exert their functions in normal development and how alterations in WT1 may lead to developmental abnormalities and tumor growth. q 2001 Elsevier Science B.V. All rights reserved. Keywords: Wilms' tumor 1 protein; Tumor suppressor; Transcriptional regulation; Splicing factors; Differentiation 1. Introduction nephrectomy, the biology of Wilms' tumors has for several reasons received a great deal of attention. A major reason is Wilms' tumor or nephroblastoma is a pediatric kidney that pediatric tumors often arise through erroneous develop- malignancy that was ®rst described by Max Wilms in ment and studying these tumors may thus offer insight into 1899. This primitive tumor affects about 1:10,000 children, embryonic development. Wilms' tumor is thought to arise usually below the age of 5 years, and accounts for approxi- from mesenchymal blastema cells that fail to differentiate mately 7.5% of all childhood tumors. into metanephric structures but continue to proliferate Although patients presenting a unilateral tumor can in ,Hastie, 1994; Machin and McCaughey, 1984). A second most cases be successfully treated with chemotherapy and reason is that Wilms' tumor is often found in association with other congenital abnormalities, the WAGR ,Wilms' tumor, aniridia, genitourinary abnormalities, mental retar- Abbreviations: AdBRK cells, adenovirus-transformed baby rat kidney dation), the Denys±Drash and the Beckwith±Wiedemann cells; CSF-I, colony stimulating factor I; CTGF, connective tissue growth syndromes, suggesting an overlap in the pathogenesis of factor; Cu,Zn-SOD, Cu,Zn-superoxide dismutase; DDS, Denys±Drash syndrome; DSRCT, desmoplastic small round cell tumor; EGF, epidermal these syndromes and Wilms' tumor ,Call et al., 1990; Gess- growth factor; EGFR, epidermal growth factor receptor; FS, Frasier ler et al., 1990; Koufos et al., 1989; Pelletier et al., 1991a). syndrome; IGF-II, insulin-like growth factor-II; IGF-IR, insulin-like Indeed, studies of the WAGR and the Beckwith±Wiede- growth factor-I receptor; MDR-1, multidrug resistance-1; MIS, MuÈllerian mann syndromes facilitated the mapping of two minimal inhibitory substance; ODC, ornithine decarboxylase; PDGF-A, platelet- critical regions on chromosome 11p13 and 11p15, respec- derived growth factor-A chain; PKA, protein kinase A; PKC, protein kinase C; RAR-a, retinoic acid receptor-a; SF-1, steroidogenic factor-1; TGF-b, tively, involved in the development of sporadic Wilms' transforming growth factor-b; TPA, 12-O-tetradecanoylphorbol-13-acet- tumor ,Bickmore et al., 1989; Call et al., 1990; Francke et ate; WAGR, Wilms' tumor, aniridia, genitourinary abnormalities and al., 1979; Gessler et al., 1990; Glaser et al., 1989; Koufos et mental retardation; WT1, Wilms' tumor 1; WTAP, Wilms' tumor 1 asso- al., 1989; Reeve et al., 1989). Third, a locus for familial ciated protein Wilms' tumor, which accounts for only 1% of all Wilms' * Corresponding author. Tel.: 131-71-5276136; fax: 131-71-5276284. E-mail address: [email protected] ,A.G. Jochemsen). tumors, is not linked to chromosome 11 ,Grundy et al., 0378-1119/01/$ - see front matter q 2001 Elsevier Science B.V. All rights reserved. PII: S0378-1119,01)00593-5 142 V. Scharnhorst et al. / Gene 273 .2001) 141±161 1988), but instead maps to other chromosomal regions native splice donor site at the end of exon 9 results in ,Rahman et al., 1996, 1997; Slater and Mannens, 1992), incorporation of three additional amino acids, lysine, threo- demonstrating that Wilms' tumors are genetically heteroge- nine and serine ,KTS), between the third and fourth zinc neous and that at least three candidate genes are implicated ®ngers. The ratio of the different WT1 splice variants was in their development. found to be conserved between normal fetal kidney, Wilms' So far, the Wilms' tumor 1 gene ,WT1) at 11p13 is the tumors and several tissues of the murine genitourinary only gene involved in development of Wilms' tumor that system. The mRNA isoform containing both splice inserts has been cloned ,Call et al., 1990; Gessler et al., 1990) and is the most prevalent variant in both human and mouse, classi®ed as a tumor suppressor gene. It is now recognized whereas the least common is the transcript missing both that WT1 is homozygously mutated in 5±10% of Wilms' inserts ,Haber et al., 1991). These ®ndings were later tumors ,Gessler et al., 1994; Little and Wells, 1997; Little extended by a report describing that splicing of exon 5 is et al., 1992). differentially regulated in a species-, tissue- and develop- mental stage-speci®c manner, while the 1KTS/2KTS ratio is maintained in all cell types tested ,Renshaw et al., 1997). 2. The WT1 gene, mRNAs and proteins Additional WT1 mRNAs are generated through RNA edit- ing at nucleotide 839 of the WT1 mRNA that replaces The human WT1 gene spans about 50 kb at chromosome leucine 280 in WT1 proteins by proline ,Sharma et al., locus 11p13 ,Call et al., 1990; Gessler et al., 1990). It 1994), although the frequency of RNA editing might be comprises ten exons and encodes mRNAs of approximately signi®cantly lower than initially published ,Mrowka and 3 kb ,Call et al., 1990; Gessler et al., 1992). Schedl, 2000). The WT1 gene may thus produce eight differ- In mammals, exons 5 and 9 of WT1 are alternatively ent mRNA isoforms, suggesting that each isoform has a spliced, giving rise to four different splice isoforms ,Fig. distinct contribution to the function of the WT1 gene and 1) ,Gessler et al., 1992; Haber et al., 1991). In all other that balanced expression of the isoforms is essential for vertebrates tested, exon 5 is not present in the WT1 gene, proper WT1 function. so that only two different mRNA transcripts are generated Depending on the absence or presence of the two splice ,Kent et al., 1995). Inclusion of exon 5 inserts 17 amino inserts, the WT1 proteins have molecular masses of 52±54 acids between the proline and glutamine-rich amino-termi- kDa ,Morris et al., 1991). The WT1,2/2) protein with a nus and the zinc-®nger domain of WT1.
Load more

Recommended publications
  • Wt1) – an Effector in Leukemogenesis?
    WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Vidovic, Karina 2010 Link to publication Citation for published version (APA): Vidovic, K. (2010). WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 07. Oct. 2021 Division of Hematology and Transfusion Medicine Lund University, Lund, Sweden WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS? Karina Vidovic Thesis 2010 Contact adress Karina Vidovic Division of Hematology and Transfusion Medicine BMC, C14 Klinikgatan 28 SE- 221 84 Lund Sweden Phone +46 46 222 07 30 e-mail: [email protected] ISBN 978-91-86443-99-3 ! Karina Vidovic Printed by Media-Tryck, Lund, Sweden 2 ”The journey of a thousand miles begins with one step” Lao Tzu (Chinese taoist), 600-531 BC 3 4 LIST OF PAPERS This thesis is based on the following papers, referred to in the text by their Roman numerals I.
    [Show full text]
  • An Integrated Genome Screen Identifies the Wnt Signaling Pathway As a Major Target of WT1
    An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1 Marianne K.-H. Kima,b, Thomas J. McGarryc, Pilib O´ Broind, Jared M. Flatowb, Aaron A.-J. Goldend, and Jonathan D. Lichta,b,1 aDivision of Hematology/Oncology and cFeinberg Cardiovascular Research Institute, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; bRobert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611; and dDepartment of Information Technology, National University of Ireland, Galway, Republic of Ireland Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved May 18, 2009 (received for review February 12, 2009) WT1, a critical regulator of kidney development, is a tumor suppressor control. A first generation of in vitro cotransfection and DNA for nephroblastoma but in some contexts functions as an oncogene. binding assays have given way to more biologically relevant exper- A limited number of direct transcriptional targets of WT1 have been iments where manipulation of WT1 levels has been accompanied identified to explain its complex roles in tumorigenesis and organo- by examination of candidate or global gene expression. Classes of genesis. In this study we performed genome-wide screening for direct WT1 targets thus identified consist of inducers of differentiation, WT1 targets, using a combination of ChIP–ChIP and expression arrays. regulators of cell growth and modulators of cell death. WT1 target Promoter regions bound by WT1 were highly G-rich and resembled genes include CDKN1A (22), a negative regulator of the cell cycle; the sites for a number of other widely expressed transcription factors AREG (23), a facilitator of kidney differentiation; WNT4 (24), a such as SP1, MAZ, and ZNF219.
    [Show full text]
  • Wilms' Tumor Gene 1 in Different Types of Cancer
    UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New Series No.1717 ISSN 0346-6612 ISBN 978-91-7601-263-5 Wilms’ tumor gene 1 in different types of cancer Xingru Li Department of Medical Biosciences, Clinical Chemistry Umeå University, Sweden Umeå 2015 Copyright © 2015 Xingru Li ISBN: 978-91-7601-263-5 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden, 2015 To my family Table of Contents Abstract .......................................................................................................... 1 Original Articles ............................................................................................. 2 Abbreviations ................................................................................................. 3 Introduction .................................................................................................... 4 WT1 (Wilms’ tumor gene 1) ...................................................................... 4 Structure of WT1 ..................................................................................... 4 WT1, the transcription factor ................................................................. 5 WT1 and its interacting partners ............................................................ 5 WT1 function .......................................................................................... 8 The tumor suppressor ........................................................................ 8 An oncogene ...................................................................................... 8 Mutations and
    [Show full text]
  • Dysregulation of Meox2 Following Wt1 Mutation in Kidney Development and Wilms Tumorigenesis
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2011 DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS LaGina M. Nosavanh LaGina Merie Nosavanh Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation Nosavanh, LaGina M. and Nosavanh, LaGina Merie, "DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS" (2011). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 203. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/203 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS by LaGina Merie Nosavanh, B.S.
    [Show full text]
  • Wilms' Tumor Suppressor Gene WT1: from Structure to Renal
    J Am Soc Nephrol 11: S106–S115, 2000 Wilms’ Tumor Suppressor Gene WT1: From Structure to Renal Pathophysiologic Features CHRISTIAN MROWKA*† and ANDREAS SCHEDL* *Max Delbru¨ck Center for Molecular Medicine and †Franz Volhard Clinic, Humboldt University of Berlin, Berlin-Buch, Germany. Abstract. Normal development of the kidney is a highly com- current understanding of the structural features of WT1, how plex process that requires precise orchestration of proliferation, they modulate the transcriptional and post-transcriptional ac- differentiation, and apoptosis. In the past few years, a number tivities of the protein, and how mutations affecting individual of genes that regulate these processes, and hence play pivotal isoforms can lead to diseased kidneys is summarized. In addi- roles in kidney development, have been identified. The Wilms’ tion, results from transgenic experiments, which have yielded tumor suppressor gene WT1 has been shown to be one of these important findings regarding the function of WT1 in vivo, are essential regulators of kidney development, and mutations in discussed. Finally, data on the unusual feature of RNA editing this gene result in the formation of tumors and developmental of WT1 transcripts are presented, and the relevance of RNA abnormalities such as the Denys-Drash and Frasier syndromes. editing for the normal functioning of the WT1 protein in the A fascinating aspect of the WT1 gene is the multitude of kidney is discussed. isoforms produced from its genomic locus. In this review, our The kidney is crucial for survival. The molecular mechanisms Structural Features underlying the development of this organ, however, are only The human WT1 gene spans approximately 50 kb and in- beginning to be elucidated.
    [Show full text]
  • Wt1 Directs the Lineage Specification of Sertoli and Granulosa Cells By
    © 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 44-53 doi:10.1242/dev.144105 RESEARCH ARTICLE Wt1 directs the lineage specification of sertoli and granulosa cells by repressing Sf1 expression Min Chen1,*, Lianjun Zhang1,2,*, Xiuhong Cui1, Xiwen Lin1, Yaqiong Li1,2, Yaqing Wang3, Yanbo Wang1,2, Yan Qin1,2, Dahua Chen1, Chunsheng Han1, Bin Zhou4, Vicki Huff5 and Fei Gao1,‡ ABSTRACT Leydig cells and theca-interstitial cells are the steroidogenic cells Supporting cells (Sertoli and granulosa) and steroidogenic cells in male and female gonads, respectively. The steroid hormones (Leydig and theca-interstitium) are two major somatic cell types in produced by steroidogenic cells play essential roles in germ cell mammalian gonads, but the mechanisms that control their development and in maintaining secondary sexual characteristics. differentiation during gonad development remain elusive. In this Leydig cells first appear in testes at E12.5, whereas theca-interstitial study, we found that deletion of Wt1 in the ovary after sex cells are observed postnatally in the ovaries along with the determination caused ectopic development of steroidogenic cells at development of ovarian follicles. The origins of Leydig cells the embryonic stage. Furthermore, differentiation of both Sertoli and (Weaver et al., 2009; Barsoum and Yao, 2010; DeFalco et al., 2011) granulosa cells was blocked when Wt1 was deleted before sex and theca cells (Liu et al., 2015) have been studied previously. determination and most genital ridge somatic cells differentiated into However, the underlying mechanism that regulates the steroidogenic cells in both male and female gonads. Further studies differentiation between supporting cells and steroidogenic cells revealed that WT1 repressed Sf1 expression by directly binding to the during gonad development is poorly understood.
    [Show full text]
  • Activation of the Wt1 Wilms' Tumor Suppressor Gene by NF-Кb
    Oncogene (1998) 16, 2033 ± 2039 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Activation of the wt1 Wilms' tumor suppressor gene by NF-kB Mohammed Dehbi1, John Hiscott2 and Jerry Pelletier1,3 1Department of Biochemistry and 3Department of Oncology, McGill University, 3655 Drummond St., MontreÂal, QueÂbec, Canada, H3G 1Y6, and 2Lady Davis Institute for Medical Research, 3755 CoÃte Ste-Catherine, Montreal, QueÂbec, Canada, H3T 1E2 The Wilm's tumor suppressor gene, wt1, is expressed in the glutamine/proline rich amino (N-) terminus of a very de®ned spatial-temporal fashion and plays a key WT1, whereas the second alternatively spliced exon role in development of the urogenital system. Trans- results in the insertion of three amino acids, KTS, acting factors governing wt1 expression are poorly between the third and the fourth zinc ®ngers (for a de®ned. The presence of putative kB binding sites within review, see Reddy and Licht, 1996). WT1 has several the wt1 gene prompted us to investigate whether key structural features of a transcription factor such as members of the NF-kB/Rel family of transcription nuclear localization, a proline/glutamine N-terminal factors are involved in regulating wt1 expression. In rich region, and a DNA-binding domain consisting of transient transfection assays, ectopic expression of p50 four zinc ®ngers. Three of the four zinc ®ngers (II, III and p65 subunits of NF-kB stimulated wt1 promoter and IV) share extensive homology with those of the activity 10 ± 30-fold. Deletion mutagenesis revealed that early growth response (EGR) family of transcription NF-kB responsiveness is mediated by a short DNA factors and consequently, WT1 can bind to, and fragment located within promoter proximal sequences of regulate, the expression of numerous genes through the major transcription start site.
    [Show full text]
  • Identification of a Tumor-Specific Methylation Site in the Wilms Tumor
    Oncogene (1998) 16, 713 ± 720 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 Identi®cation of a tumor-speci®c methylation site in the Wilms tumor suppressor gene Elena V Kleymenova, Xiaoqin Yuan, Michael E LaBate and Cheryl L Walker Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957, USA Malignant mesothelioma is one of the very few extra- tion has been shown for several tumor suppressor renal neoplasms in which the Wilms tumor suppressor genes, such as retinoblastoma gene in retinoblastomas gene (wt1) is expressed. We examined wt1 for alterations (Ohtani-Fujita et al., 1993), von Hippel-Lindau gene in in rat mesotheliomas, a well characterized animal model renal cell carcinomas (Herman et al., 1995) and p16 in for the human disease. Southern analysis revealed a epithelial cancers (Merlo et al., 1995). In tumor cells de 3.5 kb EcoRI wt1 fragment readily detectable in novo DNA methylation is proposed to occur as a result majority of mesothelioma cell lines and primary of increased activity of DNA methyltransferase (el- mesotheliomas but not in normal rat tissues. Cloning Deiry et al., 1991), an enzyme thought to be and sequencing of this fragment revealed that the responsible for maintenace and de novo DNA presence of this EcoRI fragment resulted from an in- methylation in mammals. However, the molecular ability of this enzyme to cut at a EcoRI site in intron 1 determinants of DNA methylation at speci®c CpG of wt1. This site contains potential motifs for cytosine sites in tumor cells are unknown at present.
    [Show full text]
  • Wilms' Tumour 1 (WT1) in Development, Homeostasis and Disease
    © 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 2862-2872 doi:10.1242/dev.153163 PRIMER Wilms’ tumour 1 (WT1) in development, homeostasis and disease Nicholas D. Hastie* ABSTRACT particularly those involving mesenchyme-to-epithelial transitions The study of genes mutated in human disease often leads to new (MET) and the reverse process, epithelial-to-mesenchyme transition insights into biology as well as disease mechanisms. One such gene (EMT); (3) the cellular origins of mesenchymal progenitors for a is Wilms’ tumour 1 (WT1), which plays multiple roles in development, variety of tissue types, pinpointing the key role of the mesothelium; tissue homeostasis and disease. In this Primer, I summarise how this and (4) fundamental aspects of transcription and epigenetic multifaceted gene functions in various mammalian tissues and regulation. WT1 is also an example of how protein isoforms organs, including the kidney, gonads, heart and nervous system. differing by just a few amino acids may have profoundly different This is followed by a discussion of our current understanding of the functions. Here, I provide an overview of the WT1 gene, molecular mechanisms by which WT1 and its two major isoforms highlighting how it functions in the development and homeostasis regulate these processes at the transcriptional and post- of various organs and tissues, and how its mutation can lead to transcriptional levels. disease. KEY WORDS: WT1, Developmental disorders, Homeostasis, WT1 structure, evolution and isoforms Molecular mechanisms of disease The mammalian WT1 gene is ∼50 kb in length, encoding proteins from as many as ten exons. There are at least 36 potential Introduction mammalian WT1 isoforms, the diversity created through a The Wilms’ tumour 1 (WT1) gene was first identified in 1990 as a combination of alternative transcription start sites, translation start strong candidate predisposition gene for Wilms’ tumour(Calletal., sites, splicing and RNA editing (Fig.
    [Show full text]
  • Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells
    ANTICANCER RESEARCH 36: 3715-3724 (2016) Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells KEIKO NAITOH, TAKASHI KAMIGAKI, ERIKO MATSUDA, HIROSHI IBE, SACHIKO OKADA, ERI OGUMA, YOSHIHIRO KINOSHITA, RISHU TAKIMOTO, KAORI MAKITA, SHUN OGASAWARA and SHIGENORI GOTO Seta Clinic, Tokyo, Japan Abstract. For a peptide-pulsed dendritic cell (DC) vaccine cancer vaccines with various cancer antigens in treatment of to work effectively in cancer treatment, it is significant that solid tumors (3-6). For DC-based cancer vaccines, some the target protein is expressed in cancer cells. Wilms’ tumor reports have described insufficient clinical responses despite 1 (WT1) has been identified as a molecular target for the good immunoresponses indicating delayed-type immune cell therapy of cancer. We evaluated the protein hypersensitivity (DTH) (7). Immune check-point inhibitors, expression levels of WT1 in various solid tumors, as well as such as antibodies against programmed cell death protein 1 mucin 1 (MUC1) or major histocompatibility complex (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (MHC) class l molecules. Seven hundred and thirty-eight (CTLA4), are clinically used for patients with advanced or patients whose tissue samples were examined by recurrent melanoma and non-small cell lung cancer to immunohistochemical analysis agreed to undergo DC reverse immune suppression and activate effector T cells (8, vaccine therapy. The positive staining of WT1 in tumor cells 9). Furthermore, the efficacy of immune check-point was observed in 25.3% of patients, with only 8.5% of them inhibitors was reported to correlate with disorders related to showing moderate to strong expression; moreover, WT1 TSAs, oncogenic viral proteins or DNA repair pathway tended to localize in the nucleus and cytoplasm.
    [Show full text]
  • Identification of WT1 As Determinant of Heptatocellular Carcinoma and Its
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 62), pp: 105848-105859 Research Paper Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicine Salvia chinensis Benth and its active ingredient protocatechualdehyde Ning Wang1, Hor-Yue Tan1, Yau-Tuen Chan1, Wei Guo1, Sha Li1 and Yibin Feng1 1School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong S.A.R., China Correspondence to: Yibin Feng, email: [email protected] Keywords: hepatocellular carcinoma; WT1; Wnt/β-catenin pathway; Chinese herbal medicine; molecular docking-guided bioactive ingredient identification Received: August 20, 2017 Accepted: September 22, 2017 Published: November 11, 2017 Copyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Candidates from Chinese herbal Medicine might be preferable in drug discovery as the abundant experiences of traditional use usually hint the clinical efficacy. In this study, we screened the anti-tumour effect of several commonly used Chinese herbal Medicines on human hepatocellular carcinoma cells (HCC). We identified that Salvia chinensia Benth. (Shijianchuan in Chinese, SJC) exhibited prominent in vitro inhibition of HCC cells and suppressed the orthotopic growth of HCC in the liver of mice and repressed the lung metastasis of tumour cells. Using a pathway-specific PCR array and Gene Ontology analysis, we identified that Wnt/β-catenin pathway was associated with the suppressive effect of SJC on HCC cell proliferation and cell cycle progression.
    [Show full text]
  • Changes in WT1 Splicing Are Associated with a Specific Gene
    Oncogene (2002) 21, 5566 – 5573 ª 2002 Nature Publishing Group All rights reserved 0950 – 9232/02 $25.00 www.nature.com/onc Changes in WT1 splicing are associated with a specific gene expression profile in Wilms’ tumour Dominique Baudry1, Marine Faussillon1, Marie-Odile Cabanis1, Muriel Rigolet1,6, Jean-Michel Zucker2, Catherine Patte3, Sabine Sarnacki4, Liliane Boccon-Gibod5, Claudine Junien1 and Ce´ cile Jeanpierre*,1 1INSERM U383, Hoˆpital Necker-Enfants Malades, Universite´ Rene´ Descartes, 75743 Paris Cedex 15, France; 2Institut Curie, 75248 Paris, France; 3Institut Gustave Roussy, 94805 Villejuif, France; 4Clinique Chirurgicale infantile, Hoˆpital Necker-Enfants Malades, 75743 Paris Cedex 15, France; 5Service d’Anatomie Pathologique, Hoˆpital Armand Trousseau, 75012 Paris, France Wilms’ tumour (WT) or nephroblastoma is the most accounting for 7% of cases. A family history of WT is frequent kidney cancer in children. In a previous study, observed in 2% of cases. This tumour may also arise in we reported alterations to WT1 transcription in 90% of association with rare malformation syndromes: WAGR WT tested, with decreased exon 5 +/7 isoform ratio syndrome (WT, aniridia, genitourinary malformations being the most frequent alteration (56% of WT). We and mental retardation), Denys – Drash syndrome now report an approach based on cDNA profiling of (DDS) and Beckwith – Wiedemann syndrome (BWS). tumour pools to identify genes likely to be dysregulated The WT1 gene, located at 11p13, encodes a zinc in association with a decreased WT1 exon 5 +/7 ratio. finger transcription factor involved in renal and gonad We compared the expression profiles of pools of tumours development (Hastie, 2001; Mrowka and Schedl, 2000).
    [Show full text]